Drugmakers: Commercial Franchises & Pipeline Renewal

The thesis

Own commercial drug manufacturers whose established medicines fund the next wave of patent-protected products, rather than research tools, speculative discovery platforms or a single treatment category. The opportunity is franchise renewal through approvals, new indications and pipeline execution across distinct therapeutic markets. Recent strength in several manufacturers makes this a timely, diversified healthcare allocation, while patent expirations, trial failures and reimbursement pressure